Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5188022 | 0.86 | HDAC8 (0.62) | EPHX2MAPK1HDAC8MTNR1AMTNR1B | |
| SCHEMBL8568435 | 0.86 | EPHX2 (0.68) | EPHX2MAPK1HDAC8MTNR1AMTNR1B | |
| SCHEMBL4830429 | 0.86 | EPHX2 (0.68) | EPHX2MAPK1HDAC8MTNR1AMTNR1B | |
| SCHEMBL8568429 | 0.86 | EPHX2 (0.68) | EPHX2MAPK1HDAC8MTNR1AMTNR1B | |
| SCHEMBL22469105 | 0.84 | EPHX2 (0.49) | EPHX2MAPK1HDAC8MTNR1AMTNR1B | |
| SCHEMBL22469297 | 0.84 | EPHX2 (0.49) | EPHX2MAPK1HDAC8MTNR1AMTNR1B | |
| SCHEMBL8562865 | 0.83 | EPHX2 (0.65) | EPHX2MAPK1HDAC8MTNR1AMTNR1B | |
| SCHEMBL8562858 | 0.83 | EPHX2 (0.65) | EPHX2MAPK1HDAC8MTNR1AMTNR1B | |
| SCHEMBL8561743 | 0.83 | EPHX2 (0.78) | EPHX2MAPK1HDAC8MTNR1AMTNR1B | |
| SCHEMBL8562515 | 0.83 | EPHX2 (0.61) | EPHX2MAPK1HDAC8MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124412-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| EP-4222143-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | Katholieke Universiteit Leuven (BE) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023122581-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-3760628-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-01-06 | — | — | EP | disclosed |
| US-20200407370-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2020-12-31 | — | — | US | disclosed |
| EP-3383865-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017093272-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-08 | — | — | WO | disclosed |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8350083-B2 | Antagonists of the TRPV1 receptor and uses thereof | ABBVIE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-14 | — | — | US | disclosed |
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| EP-1644335-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2006078697-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160850-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-20 | — | — | US | disclosed |
| EP-1644335-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005007628-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-20 | — | — | US | disclosed |
| US-6602883-B1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-6387926-B1 | ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | YAP1, TEAD2, TEAD1 | EPHX2 2674/4885MAPK1 1086/4885HDAC8 1805/4885 |
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | EPHX2 3104/4885MAPK1 1479/4885HDAC8 2383/4885 |
| US-20240124412-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | EPHX2 1919/4885MAPK1 4634/4885HDAC8 163/4885 |
| US-20200407370-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | PADI4, PADI2, PADI1 | EPHX2 2608/4885MAPK1 1561/4885HDAC8 1624/4885 |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | EPHX2 2878/4885MAPK1 1403/4885HDAC8 2393/4885 |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | EPHX2 1569/4885MAPK1 1461/4885HDAC8 2618/4885 |
| US-20060160850-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | EPHX2 531/4885MAPK1 2017/4885HDAC8 1200/4885 |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | EPHX2 1569/4885MAPK1 1461/4885HDAC8 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.